Skip to main content
Erschienen in: European Journal of Epidemiology 5/2017

11.05.2017 | ESSAY

Cancer subtypes in aetiological research

verfasst von: Lorenzo Richiardi, Francesco Barone-Adesi, Neil Pearce

Erschienen in: European Journal of Epidemiology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Researchers often attempt to categorize tumors into more homogeneous subtypes to better predict prognosis or understand pathogenic mechanisms. In clinical research, typically the focus is on prognosis: the tumor subtypes are intended to be associated with specific responses to treatment and/or different clinical outcomes. In aetiological research, the focus is on identifying distinct pathogenic mechanisms, which may involve different risk factors. We used directed acyclic graphs to present a framework for considering potential biases arising in aetiological research of tumor subtypes, when there is incomplete correspondence between the identified subtypes and the underlying pathogenic mechanisms. We identified two main scenarios: (1) weak effect, when the tumor subtypes are identified through combinations of characteristics and some of these characteristics are affected by factors that are unrelated with the underlying pathogenic mechanisms; and (2) lack of causality, when the set of characteristics corresponds with a mechanism that is actually not a cause of the tumor of interest. Examples of the magnitude of bias that can be introduced in these situations are provided. Although categorization of tumors into homogenous subtypes may have important implications for aetiological research and identification of risk factors, the characteristics used to classify tumors into subtypes should be as close as possible to the actual pathogenic mechanisms to avoid interpretative biases. Whenever our knowledge of these mechanisms is limited, research into risk factors for tumor subtypes should first aim to causally link the characteristics to the pathogenic mechanisms.
Literatur
2.
Zurück zum Zitat Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2016;137(5):1347–58.CrossRefPubMed Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2016;137(5):1347–58.CrossRefPubMed
3.
5.
Zurück zum Zitat Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.CrossRefPubMedPubMedCentral Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Network Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef Network Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
7.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–23.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.CrossRefPubMed Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63.CrossRefPubMed
10.
Zurück zum Zitat Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. Hum Genom. 2015;9:27.CrossRef Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. Hum Genom. 2015;9:27.CrossRef
11.
Zurück zum Zitat Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.CrossRefPubMedPubMedCentral Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.CrossRefPubMed Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.CrossRefPubMed
13.
Zurück zum Zitat Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, et al. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 2015;17(12):1589–98.CrossRefPubMedPubMedCentral Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, et al. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 2015;17(12):1589–98.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):130–44.CrossRefPubMedPubMedCentral Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014(48):130–44.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365–7.CrossRefPubMedPubMedCentral Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365–7.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465–84.CrossRefPubMedPubMedCentral Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465–84.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2016 Oct 13. Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2016 Oct 13.
20.
Zurück zum Zitat Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27(4):602–11.CrossRefPubMedPubMedCentral Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27(4):602–11.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Nishihara R, VanderWeele TJ, Shibuya K, Mittleman MA, Wang M, Field AE, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015;30(10):1129–35.CrossRefPubMedPubMedCentral Nishihara R, VanderWeele TJ, Shibuya K, Mittleman MA, Wang M, Field AE, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015;30(10):1129–35.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Porta M, Vineis P, Bolúmar F. The current deconstruction of paradoxes: one sign of the ongoing methodological “revolution”. Eur J Epidemiol. 2015;30(10):1079–87.CrossRefPubMed Porta M, Vineis P, Bolúmar F. The current deconstruction of paradoxes: one sign of the ongoing methodological “revolution”. Eur J Epidemiol. 2015;30(10):1079–87.CrossRefPubMed
23.
Zurück zum Zitat Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332(3):133–8.CrossRefPubMed Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332(3):133–8.CrossRefPubMed
24.
Zurück zum Zitat Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;185:716–25.CrossRef Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;185:716–25.CrossRef
25.
Zurück zum Zitat Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38(2):310–7.CrossRefPubMed Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38(2):310–7.CrossRefPubMed
26.
Zurück zum Zitat Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782–800.CrossRefPubMed Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35(5):782–800.CrossRefPubMed
27.
Zurück zum Zitat Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2016;7(16):398.CrossRef Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2016;7(16):398.CrossRef
28.
Zurück zum Zitat Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131(1):159–67.CrossRefPubMed Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131(1):159–67.CrossRefPubMed
29.
Zurück zum Zitat Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, et al. The molecular basis of breast cancer pathological phenotypes. J Pathol. 2017;241(3):375–91.CrossRefPubMed Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, et al. The molecular basis of breast cancer pathological phenotypes. J Pathol. 2017;241(3):375–91.CrossRefPubMed
30.
31.
Zurück zum Zitat Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst. 2014;106(8):dju165.CrossRefPubMedPubMedCentral Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst. 2014;106(8):dju165.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210–9.CrossRefPubMed Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210–9.CrossRefPubMed
33.
Zurück zum Zitat Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res. 2016;9(7):518–27.CrossRef Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res. 2016;9(7):518–27.CrossRef
34.
Zurück zum Zitat Sung H, Yang HH, Zhang H, Yang Q, Hu N, Tang ZZ, et al. Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers. Int J Epidemiol. 2015;44(4):1341–52.CrossRefPubMedPubMedCentral Sung H, Yang HH, Zhang H, Yang Q, Hu N, Tang ZZ, et al. Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers. Int J Epidemiol. 2015;44(4):1341–52.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cancer subtypes in aetiological research
verfasst von
Lorenzo Richiardi
Francesco Barone-Adesi
Neil Pearce
Publikationsdatum
11.05.2017
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 5/2017
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-017-0253-z

Weitere Artikel der Ausgabe 5/2017

European Journal of Epidemiology 5/2017 Zur Ausgabe